Cellbricks Therapeutics is founded in 2016, operates from its headquarter in Müllerstrasse 178 c/o Campus of Bayer AG Berlin, 13353, DE. The company operates in the Hospitals & Healthcare, Medical Practices sector, providing Biotechnology Company.
Cellbricks Therapeutics specializes in Synthetic biology, 3D-bioprinting, Biofabrication technology, Tissue engineering, and offers services including Bioprinted tissue therapeutics, Clinical treatments, and Human tissue replication.